Paperless precision picking at pharmaceutical wholesaler Ebert + Jacobi.
How doctors in Sweden are utlising a new database to offer up the greenest of medicines to their patients.
2009 was a momentous year in many ways, but it will always be remembered for the economic turmoil that impacted almost every country and every industry across the globe. The pharmaceutical industry once considered itself largely safe from down turns and the macro economic cycle, but last year’s events left none in doubt that there are few safe havens in such traumatic times.
Many factors are currently conspiring to change the pricing models for pharmaceuticals and/or biologicals and therefore their acceptable manufacturing costs and what constitutes acceptable time to market. These changes are, in turn, driving changes in the requirements of the modern bio-processing facility.
The only thing certain is change. This axiom holds true for many aspects of today’s world but it is a central tenet for drug development. Fifteen years ago, small molecules (chemically synthesized molecules designed to interact with a specific cellular receptor) represented the majority of pharmaceuticals under development. During the past 10 years, however, the number of therapies being developed that fall into the category of biopharmaceuticals has exploded, with predictions that the majority of therapies
developed in the next 10 years will fall into this class.